• A"er the ini*al four--week lead--in with DT, pa*ents were tested for RVR (GG strategies) or with the bio--mathema*cal model test (MG strategies). The rates of RVR and posi*ve model test were obtained from the observed valida*on cohort
INTRODUCTION
• An increasing range of an*viral treatments specific to chronic hepa**s C (CHC) is currently being made available in clinical prac*ce. Two NS3--NS4 HCV protease inhibitors, telaprevir (TVR) and boceprevir (BOC), indicated in the treatment of genotype 1 (G1) HCV in combina*on with peg--interferon alpha and ribavirin (dual therapy - DT), were introduced only a few years ago. Sofosbuvir and simeprevir are already available in the US and EU markets, while a new range of products that will not need to be used in combina*on with interferon are expected to become shortly available.
• In spite of the high efficacy and op*mal safety profile, the cost associated with these treatments, with the poten*al impact on the budget of na*onal healthcare systems in Europe represents a major concern.
• Triple therapy (TT) with peg--interferon alpha, ribavirin, and BOC or TVR increases the rates of sustained virologic response (SVR) as compared to DT in G1 treatment--naïve CHC pa*ents.
• To op*mize clinical outcomes along with overall cost, Italian clinical guidelines suggest to use TT as the first line treatment in pa*ents with advanced fibrosis (METAVIR fibrosis scores F3--F4), and to adopt TT only in F0--F2 pa*ents who are not likely to achieve SVR with DT [1] according to the main on treatment predictor of SVR, that is the achievement of undetectable HCV--RNA a"er 4 weeks of DT (rapid virologic response, RVR).
• An alterna*ve measure to iden*fy pa*ents with a high chance of SVR can be the applica*on of a bio--mathema*cal model of viral dynamics. Bio--mathema*cal modelling of HCV--RNA and alanine aminotransferase (ALT) decline during DT has already been shown to be able to predict SVR with high accuracy [2] .
OBJECTIVE
• The objec*ve of the current study was to use a simplified version of the bio--mathema*cal model developed by Colombado et al. [3] to inform a decision--analy*c model for a cost--effec*veness analysis of personalized an*--HCV therapy in an Italian sefng in treatment--naive F0--F2 pa*ents.
METHODS
• The simplified version of the bio--mathema*cal model allows the predic*on of SVR in HCV G1 pa*ents, using only two ALT measures, at week 1 and 2, in addi*on to ALT and HCV--RNA measures at baseline and week 4 necessary for RVR. This was validated in a cohort of 150 consecu*ve G1 CHC pa*ents treated with DT at the University Hospital in Pisa, Italy.
• A decision--analy*c model was developed in Microso" Excel 2011 in the perspec*ve of the Italian Na*onal Healthcare System and with a life*me *me horizon. A 3.5% discount rate was applied both to outcomes and costs.
• Two strategies were compared: guideline--guided (GG) and model--guided (MG). All simulated pa*ents received DT for four weeks and the two strategies then differed in the criterion applied to iden*fy those who could con*nue DT rather than switching to TT (RVR criterion and bio--mathema*cal model test). RVR was defined as not detectable HCV RNA levels at week 4, while the model test was defined by a threshold of residual infected cells and free virions at the end of therapy, as computed at week 4 by a decline in ALT (week 1, 2 and 4) and HCV--RNA levels (week 4). 
Long--term Markov model
• Transi*on probabili*es and health state u*li*es in the Markov model were derived from published clinical literature describing the course of the disease or from previously published economic models [8--12, 13] • Costs included drugs, strategy--related tests (based on current prices and tariffs) and the management of the long--term course of the disease. These lader costs were based on a set of annual costs (including hospitaliza*ons, specialized ac*vi*es and diagnos*c ac*vi*es) related to the different severity stages of chronic hepa**s B and C, as reported in a publica*on from the Associazione Italiana per lo Studio del Fegato (AISF) [14] . • One--way sensi*vity analysis (OWSA) and probabilis*c sensi*vity analysis (PSA) are presented for the case of the MG--TVR versus GG--TVR comparison. TVR was the protease inhibitor selected, because of the favourable ICER demonstrated when compared with BOC for both the MG and GG strategies.
• DSA was performed, varying one model parameter at a *me in the range ±10% of its base case value and assessing its impact on the net monetary benefit (NMB), which, assuming a willingness--to--pay threshold of €30,000/QALY, in the base case was €8,502 ( Figure 4 ).
• For each strategy two situa*ons were considered, with TT including the addi*on of either BOC or TVR to peg--interferon and ribavirin. In total, therefore, four strategies were compared: GG--BOC, GG--TVR, MG--BOC and MG--TVR.
• The model is formed by two modules: 1) a decision tree for the ini*al treatment period simula*ng the adop*on of the compared strategies, and; 2) a long--term Markov model to simulate the pa*ents' remaining life*me. 
CONCLUSIONS
• The adop*on of a SVR predic*ve criterion based on a bio--mathema*cal model, has the poten*al to improve the cost--effec*veness of a personalized an*--HCV therapy, allowing a more accurate iden*fica*on of pa*ents who can be effec*vely treated with DT and reserving high--cost BOC--and TVR--based TT for those who really need it.
RESULTS
• In the base case analysis, the four strategies provided similar clinical outcomes: 20.06 to 20.20 discounted LYs and 18.91 to 19.42 discounted QALYs. The total average per--pa*ent life*me costs were €28,800 and €29,900 with GG--BOC and GG--TVR, and €25,200 and €26,000 with MG--BOC and MG--TVR (Table 1 ).
• The cost--effec*veness analysis was primarily performed in terms of cost per QALY gained to compare the MG and GG strategies (keeping the choice of the protease inhibitor fixed). When comparing the MG and GG strategies, either with BOC or TVR, the former was marginally more effec*ve and less costly (dominant) ( Table 2 ).
